Proteomics leadership CDI Labs holds the world’s largest collection of proteomes and offers proteome-wide antibody profiling, target identification, and biomarker discovery, presenting a clear opportunity to upsell comprehensive proteomics services to pharma and biotech clients seeking broad molecular insights.

PhIP-Seq expansion Recent launch of VirScan, HuScan, and MouseScan services expands capabilities in antigen-specific profiling, enabling targeted outreach to customers pursuing immune profiling, vaccine research, or autoimmune biomarker programs.

Clinical and therapeutic scope Through immunogenicity assessments for cell, gene, and radioligand therapies and antibody specificity profiling, CDI Labs positions itself to engage biotechs and sponsors advancing novel therapies that require detailed immunology and safety profiling.

Strategic partnerships Existing platforms and curated arrays (HuProt) plus cloud-based tech stack indicate readiness for scalable collaborations with CROs, biopharma, and academic partners seeking high-throughput, proteome-scale data generation.

Growth indicators revenue range and recent service launches suggest expanding demand for proteome-wide assays and biomarker discovery, presenting opportunities for expanded program additions, tiered offerings, and international collaboration through CDI Labs Canada.